Keywords: good, prospects, ares-serono, rebif, interferon, beta-1b, treatment
Good Prospects For Ares-Serono's Rebif?
Article | 26 March 1998
Ares-Serono's Rebif (interferon beta-1b), for the treatment of relapsingremitting multiple sclerosis, is forecast to achieve peak global sales of $340 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
